Transforming Data Into Actionable Insights in the Lab

SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoother.  Laboratories are facing increasing complexity and growing testing demand.

PRNewsWire • 4 hours ago

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financial results for the third quarter 2026 ended September 27, 2026, shortly after the market closes at 4:00 p.m. ET on Tuesday, November 3, 2026.

PRNewsWire • Oct 20, 2026

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of equity awards to two newly hired, non-executive employees (the "Inducement Grants"). The Inducement Grants were granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to each employee's entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

PRNewsWire • Oct 15, 2026

Reasons to Add QuidelOrtho Stock to Your Portfolio for Now

QDEL's strong Q2 results, diversified product portfolio and cost-saving initiatives bolster its growth prospects despite persistent weakness in respiratory demand.

Zacks Investment Research • Oct 14, 2026

Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Oct 8, 2026

QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. Mr. Sharma brings more than 20 years of experience across investor relations, corporate strategy and equity research at global organizations.

PRNewsWire • Oct 7, 2026

Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.

PRNewsWire • Sep 24, 2026

Faster Answers, Better Decisions: ADLM 2026 Highlights

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.

PRNewsWire • Aug 27, 2026

QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

Zacks Investment Research • Aug 17, 2026

Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

Zacks Investment Research • Aug 17, 2026